Intra-Cellular Therapies Inc
NASDAQ:ITCI

Watchlist Manager
Intra-Cellular Therapies Inc Logo
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Watchlist
Price: 131.87 USD -0.04%
Market Cap: 14B USD
Section:
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ITCI stock under the Base Case scenario is 53.91 USD. Compared to the current market price of 131.87 USD, Intra-Cellular Therapies Inc is Overvalued by 59%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ITCI Relative Value
Base Case
53.91 USD
Overvaluation 59%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

20.6
P/S
P/S
Price to Sales
20.6
vs History
42
vs Industry
8
Median 3Y
16.7
Median 5Y
20.6
Industry
2.6
Forward
14.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-60
Median 5Y
-25
Industry
21.8
Forward
658.9
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-67.7
Median 5Y
-23
Industry
16.5
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-67.7
Median 5Y
-23
Industry
22.8
More Details
12.2
P/B
P/B
Price to Book Value
12.2
vs History
0
vs Industry
5
Median 3Y
9.6
Median 5Y
7.7
Industry
2.3
More Details
19.1
EV/S
EV/S
Enterprise Value to Sales
19.1
vs History
42
vs Industry
8
Median 3Y
15.2
Median 5Y
19.1
Industry
2.8
Forward
13.5
More Details
20.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
20.9
vs History
42
vs Industry
10
Median 3Y
16.4
Median 5Y
20.9
Industry
5.4
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-47
Median 5Y
-21.6
Industry
12.7
Forward
448.2
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-46.8
Median 5Y
-21.6
Industry
16.3
Forward
-1 119.5
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-62.9
Median 5Y
-20.9
Industry
15.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-62.9
Median 5Y
-20.8
Industry
17.7
More Details
38.3
EV/IC
EV/IC
Enterprise Value to IC
38.3
vs History
25
vs Industry
3
Median 3Y
27.7
Median 5Y
33.2
Industry
2
More Details

Multiples Across Competitors

ITCI Competitors Multiples
Intra-Cellular Therapies Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Intra-Cellular Therapies Inc
NASDAQ:ITCI
14B USD 20.6 -187.6 -111.9 -111.5
US
Eli Lilly and Co
NYSE:LLY
920.3B USD 15.4 49.7 33.4 35.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
456.1B USD 4.9 18 14.8 19.2
CH
Roche Holding AG
SIX:ROG
226.8B CHF 3.7 23.9 10.8 12.3
UK
AstraZeneca PLC
LSE:AZN
208B GBP 4.7 29.1 108.1 158.1
CH
Novartis AG
SIX:NOVN
197.9B CHF 4.4 17 10.8 14
US
Merck & Co Inc
NYSE:MRK
215.8B USD 3.4 11.3 8.2 9.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.2 12.9 9 10.5
IE
Endo International PLC
LSE:0Y5F
202B USD 87.1 -69.1 320.4 803.4
US
Pfizer Inc
NYSE:PFE
140B USD 2.2 14.1 7.3 9.9
P/E Multiple
Earnings Growth PEG
US
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Average P/E: 22
Negative Multiple: -187.6 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
49.7
50%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
18
29%
0.6
CH
Roche Holding AG
SIX:ROG
23.9
29%
0.8
UK
AstraZeneca PLC
LSE:AZN
29.1
38%
0.8
CH
Novartis AG
SIX:NOVN
17
18%
0.9
US
Merck & Co Inc
NYSE:MRK
11.3
15%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
7%
1.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.1 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.1
31%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Average EV/EBITDA: 436.9
Negative Multiple: -111.9 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.4
30%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
14.8
8%
1.9
CH
Roche Holding AG
SIX:ROG
10.8
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
108.1
10%
10.8
CH
Novartis AG
SIX:NOVN
10.8
6%
1.8
US
Merck & Co Inc
NYSE:MRK
8.2
7%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
9
6%
1.5
IE
E
Endo International PLC
LSE:0Y5F
320.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.3
1%
7.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Average EV/EBIT: 1 877.5
Negative Multiple: -111.5 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.8
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
19.2
14%
1.4
CH
Roche Holding AG
SIX:ROG
12.3
6%
2
UK
AstraZeneca PLC
LSE:AZN
158.1
22%
7.2
CH
Novartis AG
SIX:NOVN
14
12%
1.2
US
Merck & Co Inc
NYSE:MRK
9.7
9%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
10.5
6%
1.8
IE
E
Endo International PLC
LSE:0Y5F
803.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
9.9
10%
1

See Also

Summary
ITCI intrinsic value, competitors valuation, and company profile.
DCF Valuation
ITCI stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ITCI stock valuation using valuation multiples.
Wall Street Estimates
ITCI price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ITCI stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 295,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.